Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.55%
1,100.22
-6.14
-0.55%
—1,106.361,105.681,109.291,096.52——
SIXC
Communications
SIXC
Communications
SIXC
+0.47%
613.18
+2.89
+0.47%
—610.29610.29616.60610.29——
SIXE
Energy
SIXE
Energy
SIXE
+0.76%
1,220.41
+9.19
+0.76%
—1,211.221,211.011,221.341,208.50——
SIXI
Industrials
SIXI
Industrials
SIXI
+0.24%
1,754.87
+4.16
+0.24%
—1,750.711,753.101,762.131,743.30——
SIXM
Financials
SIXM
Financials
SIXM
+0.51%
631.38
+3.21
+0.51%
—628.17629.38634.09629.38——
SIXR
Staples
SIXR
Staples
SIXR
+0.54%
859.17
+4.60
+0.54%
—854.57855.71860.09855.45——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.40%
216.01
-0.86
-0.40%
—216.87216.87217.79216.13——
SIXT
Technology
SIXT
Technology
SIXT
+1.08%
3,600.40
+38.46
+1.08%
—3,561.943,571.443,628.583,562.15——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.02%
903.45
+0.14
+0.02%
—903.31903.26906.56901.18——
SIXV
Health care
SIXV
Health care
SIXV
-0.04%
1,480.99
-0.55
-0.04%
—1,481.541,482.481,488.461,474.18——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.29%
2,406.91
+6.96
+0.29%
—2,399.952,404.452,418.812,398.09——
JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
$230.34
-0.86%
(-1.99) 1D
May 14, 1:24:09 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for JAZZ...
Open
$232.84
High
$233.95
Low
$229.92
Mkt. cap
14.45B
Avg. vol.
965.51K
Volume
317.06K
P/E ratio
2,166.07
52-wk high
$234.00
52-wk low
$103.60
EPS
$0.11
Beta
0.27
Shares outstanding
62.74M
No. of employees
3K
News stories
From sources across the web
Profile
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
About Jazz Pharmaceuticals PLC
CEOBruce C Cozadd
Employees2.89K
Founded2003
Headquarters-
SectorPharmaceutical industry
Websitejazzpharma.com
Last report
May 5, 2026
Fiscal Period
Q1 2026
EPS / Est. (USD)
$6.34 / $4.63
+36.79%beat
Revenue / Est. (USD)
1.07B / 979.34M
+9.14%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.05B
1.13B
1.20B
1.07B
Cost of goods sold
116.27M
128.88M
112.92M
96.60M
Cost of revenue
116.27M
128.88M
112.92M
96.60M
Research and development expenses
189.97M
198.20M
172.66M
196.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
358.40M
379.15M
418.46M
352.70M
Operating expense
710.47M
745.72M
760.86M
721.00M
Total operating expenses
826.74M
874.60M
873.79M
817.60M
Operating income
218.97M
251.51M
324.14M
251.30M
Other non operating income
-
-
-
122.80M
EBT including unusual items
-735.64M
8.99M
208.41M
299.20M
EBT excluding unusual items
169.72M
202.99M
278.02M
336.70M
Income tax expense
-17.17M
-242.42M
4.96M
6.10M
Effective tax rate
2.33%
-2,697.20%
2.38%
2.04%
Other operating expenses
-
-
-
-
Net income
-718.47M
251.41M
203.45M
293.10M
Net profit margin
-68.71%
22.33%
16.98%
27.42%
Earnings per share
-8.25
8.13
6.64
6.34
Interest and investment income
19.10M
18.60M
20.50M
23.40M
Interest expense
-66.46M
-67.18M
-65.91M
-63.30M
Net interest expenses
-47.36M
-48.58M
-45.41M
-39.90M
Depreciation and amortization charges
-
-
-
-
EBITDA
392.98M
429.76M
503.31M
432.70M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer